Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$23.58 USD
+0.35 (1.51%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $26.00 +2.42 (10.26%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GPCR 23.58 +0.35(1.51%)
Will GPCR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
Other News for GPCR
Crossed Above 200 Day Moving Average appears for GPCR after 7.3% move
Structure Therapeutics (GPCR) Shares Cross Above 200 DMA
New Uptrend appears for GPCR after 0.64% move
Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
Cantor Fitzgerald Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)